Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Lancet
Ralf GutzmerPaolo A Ascierto

Abstract

IMspire150 aimed to evaluate first-line combination treatment with BRAF plus MEK inhibitors and immune checkpoint therapy in BRAFV600 mutation-positive advanced or metastatic melanoma. IMspire150 was a randomised, double-blind, placebo-controlled phase 3 study done at 112 institutes in 20 countries. Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned 1:1 to 28-day cycles of atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) or atezolizumab placebo, vemurafenib, and cobimetinib (control group). In cycle 1, all patients received vemurafenib and cobimetinib only; atezolizumab placebo was added from cycle 2 onward. Randomisation was stratified by lactate dehydrogenase concentration and geographical region. Blinding for atezolizumab was achieved by means of an identical intravenous placebo, and blinding for vemurafenib was achieved by means of a placebo tablet. The primary outcome was investigator-assessed progression-free survival. This trial (ClinicalTrials.gov, NCT02908672) is ongoing but no longer recruiting patients. Between Jan 13, 2017, and April 26, 2018, 777 patients were screened and 514 were enrolled and randomly assigned to the atezolizumab group (n=256) or co...Continue Reading

Citations

May 22, 2020·Expert Review of Anticancer Therapy·Qian QinMatthew D Galsky
Jun 25, 2020·Cancers·Paolo BeccoMassimo Aglietta
Sep 20, 2020·Life·Taku FujimuraSetsuya Aiba
Dec 1, 2020·Deutsche medizinische Wochenschrift·Oana-Diana Persa, Cornelia Mauch
Dec 2, 2020·International Journal of Molecular Sciences·Kevinn Eddy, Suzie Chen
Dec 2, 2020·International Journal of Molecular Sciences·Olamide T OlaobaEstelle Leclerc
Dec 2, 2020·International Journal of Molecular Sciences·Angela DjananiManuel Maglione
Dec 5, 2020·Cancer Immunology, Immunotherapy : CII·Lukas PeifferJürgen C Becker
Dec 19, 2020·Japanese Journal of Clinical Oncology·Yukiko Kiniwa, Ryuhei Okuyama
Jan 8, 2021·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Daniel J PrzybylskiJennifer K Piccolo
Jan 5, 2021·Current Opinion in Oncology·Alvaro MoreiraLucie Heinzerling
Feb 7, 2021·Current Oncology Reports·Lauren DennisonMark Yarchoan
Jan 6, 2021·Current Opinion in Oncology·Claudia TrojanielloPaolo A Ascierto
Oct 30, 2020·Nature Communications·Shaima'a HamarshehRobert Zeiser
Jan 10, 2021·International Journal of Molecular Sciences·Paola SavoiaOttavio Cremona
Jan 14, 2021·Cancers·Alvaro MoreiraPhilip Friedlander
Nov 19, 2020·Journal of Experimental Pharmacology·Sarah K Cimino, Cathy Eng
Dec 29, 2020·American Journal of Clinical Dermatology·Ozgecan DulgarZeynep Eroglu
Feb 4, 2021·Pharmaceuticals·Florian HuemerRichard Greil
Nov 12, 2020·International Journal of Molecular Sciences·Aleksandra SimiczyjewDorota Nowak
Dec 3, 2020·Cells·Pasquale PisapiaGiancarlo Troncone
Jan 22, 2021·Pigment Cell & Melanoma Research·Sergio Jobim de AzevedoAlberto Wainstein
Dec 29, 2020·Journal for Immunotherapy of Cancer·Pier Francesco FerrucciUNKNOWN KEYNOTE-022 international team
Mar 9, 2021·Expert Review of Pharmacoeconomics & Outcomes Research·Zhiguang YangFeng Chang
Mar 10, 2021·Expert Opinion on Emerging Drugs·Vito VanellaPaolo Antonio Ascierto
Feb 20, 2021·Otolaryngologic Clinics of North America·Melissa A Wilson, Leslie A Fecher
Mar 1, 2021·Current Treatment Options in Oncology·Briana R Halle, Douglas B Johnson
Dec 8, 2020·Lancet·Funda Meric-BernstamChiara Bonini
Mar 8, 2021·The AAPS Journal·Julianne D Twomey, Baolin Zhang
Mar 16, 2021·Integrative Cancer Therapies·Siddhartha SoodSiyaram Pandey
Mar 19, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sarah KnispelLisa Zimmer
Mar 26, 2021·American Journal of Clinical Dermatology·Dimitrios C ZiogasHelen Gogas
Apr 3, 2021·The Journal of Investigative Dermatology·Franziska Noelle HarbersFang Zhao
Apr 4, 2021·Cancers·Meet PatelNeelu Puri
Apr 4, 2021·International Journal of Molecular Sciences·Alexander C ChaconPeter A Prieto
Apr 4, 2021·International Journal of Molecular Sciences·Margaret Ottaviano On Behalf Of Scito Youth
Apr 4, 2021·Cancers·Julian SteiningerFriedegund Meier
Apr 4, 2021·Cancer Discovery·Padmanee SharmaJames P Allison

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.